CNTN CNTN R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by CNTN in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: CNTN’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about CNTN's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CNTN's r&d credit carryforward?
- CNTN (CNTN) reported r&d credit carryforward of $382K in Q4 2024.
- What is the long-term trend for CNTN's r&d credit carryforward?
- Over 4 years (2020 to 2024), CNTN's r&d credit carryforward has grown at a 55.1% compound annual growth rate (CAGR), from $66K to $382K.
- What does r&d credit carryforward mean?
- This represents the accumulated value of research and development tax credits that a company has earned but has not yet utilized to offset future tax liabilities. For biotechnology firms, these carryforwards are critical assets that can provide significant tax shields once the company achieves profitability. Monitoring this balance helps investors assess the potential future tax savings available to the firm as it transitions from clinical development to commercialization.